Can pharmacogenomics improve malaria drug policy?;La pharmacogénomique peut-elle améliorer la politique des médicaments contre le paludisme?

Bulletin of the World Health Organization

Volumn 89, Issue 11, 2011, Pages 838-845

  Roederer, Mary W ^a   McLeod, HowardLeod ^a   Juliano, Jonathan J ^b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; BENFLUMETOL; CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; MEFLOQUINE; PRIMAQUINE; PYRIMETHAMINE PLUS SULFADOXINE;

DISEASE TREATMENT; DRUG DEVELOPMENT; DRUG RESISTANCE; GENETIC VARIATION; GENOMICS; HEALTH CARE; HEALTH POLICY; MALARIA; PUBLIC HEALTH; TOXICITY;

AGRANULOCYTOSIS; ANTIMALARIAL DRUG RESISTANCE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG CHOICE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULARY; DRUG LEGISLATION; DRUG METABOLISM; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ENDEMIC DISEASE; ETHNIC DIFFERENCE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GHANA; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MEDICAL DECISION MAKING; PHARMACOGENOMICS; POPULATION GENETICS; PUBLIC HEALTH; REVIEW; THAILAND; WORLD HEALTH ORGANIZATION;

AFRICA; ANTIMALARIALS; DECISION MAKING; DRUG THERAPY, COMBINATION; GENETIC VARIATION; HEALTH POLICY; HEALTH PROMOTION; HUMANS; MALARIA, FALCIPARUM; PHARMACOGENETICS; PHARMACOPOEIAS AS TOPIC; PROGRAM DEVELOPMENT; PUBLIC HEALTH; SOCIAL MARKETING; WORLD HEALTH;

EID: 80055107871     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.11.087320     Document Type: Review

References (49)

1. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006. Available from: http://whqlibdoc.who.int/publications/2006/9241546948_eng_full.pdf [accessed 23 August 2011].
2. Lin JT, Juliano JJ, Wongsrichanalai C. Drug-resistant malaria: the era of ACT. Curr Infect Dis Rep 2010;12:165-73. doi:10.1007/s11908-010-0099-y PMID:21308525
3. World malaria report 2009. Geneva: World Health Organization; 2009. Available from: http://whqlibdoc.who.int/publications/2009/9789241563901_eng.pdf [accessed 23 August 2011].
4. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 2004;71:179-86. PMID:15331836
5. Carson PE, Flanagan CL, Ickes CE, Alving AS. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956;124:484-5. doi:10.1126/science.124.3220.484-a PMID:13360274
6. Luzzatto L. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet 2010;376:739-41. doi:10.1016/S0140-6736(10)60396-0 PMID:20599264
7. Update on GSK's malaria treatments: Dacart and Lapdap. [media release]. 29 February 2008. Brentford: GlaxoSmithKline;2008. Available from: http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_0014.htm. [accessed 23 August 2011].
8. Basco LK, Ringwald P. Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaounde, Cameroon. J Infect Dis 2001;183:1828-31. doi:10.1086/320726 PMID:11372041
9. Berens N, Schwoebel B, Jordan S, Vanisaveth V, Phetsouvanh R, Christophel EM etal. Plasmodium falciparum: correlation of in vivo resistance to chloroquine and antifolates with genetic polymorphisms in isolates from the south of Lao PDR. Trop Med Int Health 2003;8:775-82. doi:10.1046/j.1365-3156.2003.01099.x PMID:12950663
10. Happi TC, Thomas SM, Gbotosho GO, Falade CO, Akinboye DO, Gerena L etal. Point mutations in the pfcrt and pfmdr-1 genes of Plasmodium falciparum and clinical response to chloroquine, among malaria patients from Nigeria. Ann Trop Med Parasitol 2003;97:439-51. doi:10.1179/000349803235002489 PMID:12930607
11. Maguire JD, Susanti AI, Kristin, Sismadi P, Fryauff DJ, Baird JK. The T76 mutation in the pfcrt gene of Plasmodium falciparum and clinical chloroquine resistance phenotypes in Papua, Indonesia. Ann Trop Med Parasitol 2001;95:559-72. doi:10.1080/00034980120092516 PMID:11672462
12. Nelson AL, Purfield A, McDaniel P, Uthaimongkol N, Buathong N, Sriwichai S etal. pfmdr1 genotyping and in vivo mefloquine resistance on the Thai-Myanmar border. Am J Trop Med Hyg 2005;72:586-92. PMID:15891133
13. Ochong EO, van den Broek IV, Keus K, Nzila A. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg 2003;69:184-7. PMID:13677373
14. Omar SA, Adagu IS, Warhurst DC. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 2001;95:315-9. doi:10.1016/S0035-9203(01)90250-0 PMID:11491006
15. Pillai DR, Labbe AC, Vanisaveth V, Hongvangthong B, Pomphida S, Inkathone S etal. Plasmodium falciparum malaria in Laos: chloroquine treatment outcome and predictive value of molecular markers. J Infect Dis 2001;183:789-95. doi:10.1086/318836 PMID:11181156
16. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004;364:438-47. doi:10.1016/S0140-6736(04)16767-6 PMID:15288742
17. Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH etal. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis 2009;9:760-74. doi:10.1016/S1473-3099(09)70320-2 PMID:19926036
18. Mehlotra RK, Henry-Halldin CN, Zimmerman PA. Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics 2009;10:435-49. doi:10.2217/14622416.10.3.435 PMID:19290792
19. Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, Singer CR etal. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986;327:411-4. doi:10.1016/S0140-6736(86)92371-8 PMID:2868340
20. Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 1990;83:82-5. PMID:2138674
21. Raymond JM, Dumas F, Baldit C, Couzigou P, Beraud C, Amouretti M. Fatal acute hepatitis due to amodiaquine. J Clin Gastroenterol 1989;11:602-3. doi:10.1097/00004836-198910000-00034 PMID:2794450
22. Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P etal. Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol 2008;64:683-90. doi:10.1007/s00228-007-0452-8 PMID:18415093
23. Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH etal. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis 2009;9:760-74. doi:10.1016/S1473-3099(09)70320-2 PMID:19926036
24. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 2002;300:399-407. doi:10.1124/jpet.300.2.399 PMID:11805197
25. Roederer MW. Cytochrome P450 enzymes and genotype-guided drug therapy. Curr Opin Mol Ther 2009;11:632-40. PMID:20072940
26. Clarke JB, Maggs JL, Kitteringham NR, Park BK. Immunogenicity of amodiaquine in the rat. Int Arch Allergy Appl Immunol 1990;91:335-42. doi:10.1159/000235138 PMID:2210868
27. Harrison AC, Kitteringham NR, Clarke JB, Park BK. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem Pharmacol 1992;43:1421-30. doi:10.1016/0006-2952(92)90198-R PMID:1567466
28. Jewell H, Maggs JL, Harrison AC, O'Neill PM, Ruscoe JE, Park BK. Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica 1995;25:199-217. doi:10.3109/00498259509061845 PMID:7618347
29. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI etal. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607. doi:10.1097/00008571-200110000-00006 PMID:11668219
30. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007;82:197-203. doi:10.1038/sj.clpt.6100122 PMID:17361129
31. Adjei GO, Kristensen K, Goka BQ, Hoegberg LC, Alifrangis M, Rodrigues OP et al. Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother 2008;52:4400-6. doi:10.1128/AAC.00673-07 PMID:18779360
32. Cavaco I, Strömberg-Nörklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL etal. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol 2005;61:15-8. doi:10.1007/s00228-004-0871-8 PMID:15785959
33. The health sector in Ghana: facts and figures, 2008. Accra: Ghana Health Service; 2008. Available from: http://www.ghanahealthservice.org/includes/upload/publications/Facts%20and%20Figures%202008.pdf [accessed 23 August 2011].
34. Drug prices for artesunate/amodiaquine. International Drug Price Indicator Guide. Cambridge: Management Sciences for Health; 2009. Available from: http://erc.msh.org [accessed 23 August 2011].
35. Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 2003;59:429-42. doi:10.1007/s00228-003-0636-9 PMID:12920490
36. Di YM, Chow VD, Yang LP, Zhou SF. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr Drug Metab 2009;10:754-80. doi:10.2174/138920009789895507 PMID:19702528
37. Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B etal. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos 2002;30:1005-12. doi:10.1124/dmd.30.9.1005 PMID:12167566
38. Gyamfi MA, Fujieda M, Kiyotani K, Yamazaki H, Kamataki T. High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana. Eur J Clin Pharmacol 2005;60:855-7. doi:10.1007/s00228-004-0854-9 PMID:15660270
39. Yusof W, Gan SH. High prevalence of CYP2A6*4 and CYP2A6*9 alleles detected among a Malaysian population. Clin Chim Acta 2009;403:105-9. doi:10.1016/j.cca.2009.01.032 PMID:19361454
40. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008;320:330-4. doi:10.1126/science.1155165 PMID:18420924
41. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J Med 2009;361:540-1. doi:10.1056/NEJMc0900231 PMID:19641219
42. Harnessing genomic technologies towards improving health in Africa. Bethesda: Human Heredity and Health in Africa Initiative; 2011. Available from: http://www.h3africa.org/whitepaper.cfm [accessed 23 August 2011].
43. Marsh S, Van Booven DJ, McLeod HL. Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics 2006;7:625-31. doi:10.2217/14622416.7.4.625 PMID:16753009
44. Hardy BJ, Seguin B, Goodsaid F, Jimenez-Sanchez G, Singer PA, Daar AS. The next steps for genomic medicine: challenges and opportunities for the developing world. Nat Rev Genet 2008;9(Suppl 1):S23-7. doi:10.1038/nrg2444 PMID:18802418
45. Hardy BJ, Seguin B, Singer PA, Mukerji M, Brahmachari SK, Daar AS. From diversity to delivery: the case of the Indian Genome Variation initiative. Nat Rev Genet 2008;9(Suppl 1):S9-14. doi:10.1038/nrg2440 PMID:18802420
46. Hardy BJ, Seguin B, Ramesar R, Singer PA, Daar AS. South Africa: from species cradle to genomic applications. Nat Rev Genet 2008;9(Suppl 1):S19-23. doi:10.1038/nrg2441 PMID:18802417
47. Sirugo G, Schim van der Loeff M, Sam O, Nyan O, Pinder M, Hill AV etal. A national DNA bank in The Gambia, West Africa, and genomic research in developing countries. Nat Genet 2004;36:785-6. doi:10.1038/ng0804-785 PMID:15284842
48. Matimba A, Oluka MN, Ebeshi BU, Sayi J, Bolaji OO, Guantai AN etal. Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 2008;16:780-3. doi:10.1038/ejhg.2008.49 PMID:18382479
49. Ndomondo-Sigonda M, Ambali A. The african medicines regulatory harmonization initiative: rationale and benefits. Clin Pharmacol Ther 2011;89:176-8. doi:10.1038/clpt.2010.299 PMID:21252936